Lone Pine Capital’s Exact Sciences EXAS Stock Holding History

Lone Pine Capital’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,298,001	Closed	-$52.3M	–	31
2018 Q1	$52.3M	Buy	+1,298,001	New	+$63.3M	0.27%	29

Other funds holding EXAS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Lone Pine Capital's EXAS Position: Q2 2018 in Review

Lone Pine Capital sold out of Exact Sciences (EXAS) in Q2 2018, closing a stake of 1,298,001 shares — an estimated $52.3M sold.

Lone Pine Capital first reported a position in EXAS in Q1 2018 and held it in 1 quarter. The position peaked at $52.3M in Q1 2018. 349 funds tracked by Wall St. Rank hold EXAS as of Q2 2018.

Lone Pine Capital reported no remaining Exact Sciences position as of Q2 2018 after selling out during the quarter.
Lone Pine Capital sold 1,298,001 Exact Sciences shares in Q2 2018, an estimated $52.3M.
Lone Pine Capital first reported a position in Exact Sciences in Q1 2018 and held it in 1 quarter.
Lone Pine Capital's Exact Sciences position peaked at $52.3M in Q1 2018.
349 funds tracked by Wall St. Rank held Exact Sciences as of Q2 2018.

Based on Lone Pine Capital's 13F filing for Q2 2018, filed 14 Aug 2018.